PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer

Rachel Woodford; Deborah Zhou; Sarah J. Lord; Ian Marschner; Wendy A. Cooper; Craig R. Lewis; Thomas John; James Chih-Hsin Yang; Chee Khoon Lee

doi:10.2217/fon-2021-1184

PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer

Rachel Woodford, Deborah Zhou, Sarah J. Lord, Ian Marschner, Wendy A. Cooper, Craig R. Lewis, Thomas John, James Chih-Hsin Yang, Chee Khoon Lee

Western Sydney University

Research output: Contribution to journal › Article › peer-review

Abstract

Background: In metastatic non-small-cell lung cancer (mNSCLC), PD-L1 expression is associated with benefit from immune checkpoint inhibitor (ICI) therapy. However, the significance of PD-L1 expression in chemotherapy-treated patients is uncertain. Methods: Using the chemotherapy control arm of first-line randomized trials, a meta-analysis of the association between efficacy outcomes and PD-L1 status was performed, stratified by assay due to inter-assay differences. Results: Across 12 trials and 4378 patients, overall survival (OS) was superior in high PD-L1 versus negative tumors and low versus negative according to 22C3/28-8 assays. When classified by SP142 assay, no significant difference in response or survival was seen between PD-L1 groups. Conclusion: In mNSCLC, high PD-L1-expressing tumors are associated with longer OS and improved objective rate when treated with chemotherapy. Inter-assay variability impacts outcome results.

Original language	English
Pages (from-to)	1793-1799
Number of pages	7
Journal	Future Oncology
Volume	18
Issue number	14
DOIs	https://doi.org/10.2217/fon-2021-1184
Publication status	Published - 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2021-1184

Cite this

@article{8e7d5add63494418b4fa5ce142869bde,

title = "PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer",

abstract = "Background: In metastatic non-small-cell lung cancer (mNSCLC), PD-L1 expression is associated with benefit from immune checkpoint inhibitor (ICI) therapy. However, the significance of PD-L1 expression in chemotherapy-treated patients is uncertain. Methods: Using the chemotherapy control arm of first-line randomized trials, a meta-analysis of the association between efficacy outcomes and PD-L1 status was performed, stratified by assay due to inter-assay differences. Results: Across 12 trials and 4378 patients, overall survival (OS) was superior in high PD-L1 versus negative tumors and low versus negative according to 22C3/28-8 assays. When classified by SP142 assay, no significant difference in response or survival was seen between PD-L1 groups. Conclusion: In mNSCLC, high PD-L1-expressing tumors are associated with longer OS and improved objective rate when treated with chemotherapy. Inter-assay variability impacts outcome results.",

author = "Rachel Woodford and Deborah Zhou and Lord, {Sarah J.} and Ian Marschner and Cooper, {Wendy A.} and Lewis, {Craig R.} and Thomas John and Yang, {James Chih-Hsin} and Lee, {Chee Khoon}",

year = "2022",

doi = "10.2217/fon-2021-1184",

language = "English",

volume = "18",

pages = "1793--1799",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine ",

number = "14",

}

TY - JOUR

T1 - PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer

AU - Woodford, Rachel

AU - Zhou, Deborah

AU - Lord, Sarah J.

AU - Marschner, Ian

AU - Cooper, Wendy A.

AU - Lewis, Craig R.

AU - John, Thomas

AU - Yang, James Chih-Hsin

AU - Lee, Chee Khoon

PY - 2022

Y1 - 2022

N2 - Background: In metastatic non-small-cell lung cancer (mNSCLC), PD-L1 expression is associated with benefit from immune checkpoint inhibitor (ICI) therapy. However, the significance of PD-L1 expression in chemotherapy-treated patients is uncertain. Methods: Using the chemotherapy control arm of first-line randomized trials, a meta-analysis of the association between efficacy outcomes and PD-L1 status was performed, stratified by assay due to inter-assay differences. Results: Across 12 trials and 4378 patients, overall survival (OS) was superior in high PD-L1 versus negative tumors and low versus negative according to 22C3/28-8 assays. When classified by SP142 assay, no significant difference in response or survival was seen between PD-L1 groups. Conclusion: In mNSCLC, high PD-L1-expressing tumors are associated with longer OS and improved objective rate when treated with chemotherapy. Inter-assay variability impacts outcome results.

AB - Background: In metastatic non-small-cell lung cancer (mNSCLC), PD-L1 expression is associated with benefit from immune checkpoint inhibitor (ICI) therapy. However, the significance of PD-L1 expression in chemotherapy-treated patients is uncertain. Methods: Using the chemotherapy control arm of first-line randomized trials, a meta-analysis of the association between efficacy outcomes and PD-L1 status was performed, stratified by assay due to inter-assay differences. Results: Across 12 trials and 4378 patients, overall survival (OS) was superior in high PD-L1 versus negative tumors and low versus negative according to 22C3/28-8 assays. When classified by SP142 assay, no significant difference in response or survival was seen between PD-L1 groups. Conclusion: In mNSCLC, high PD-L1-expressing tumors are associated with longer OS and improved objective rate when treated with chemotherapy. Inter-assay variability impacts outcome results.

UR - https://hdl.handle.net/1959.7/uws:70387

U2 - 10.2217/fon-2021-1184

DO - 10.2217/fon-2021-1184

M3 - Article

SN - 1479-6694

VL - 18

SP - 1793

EP - 1799

JO - Future Oncology

JF - Future Oncology

IS - 14

ER -

PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this